Want to see GB:ABDX full AI Analyst Report?
Top Page
Abingdon Health PLC
(LSE:ABDX)
Select Model
Select Model
Rating:46Neutral
Price Target:
9.00 p
▼(-18.18% Downside)
Action:Reiterated
Date:10/16/26
The score is held down mainly by weak financial performance (continued net losses and negative free cash flow) and bearish technicals (trading below major moving averages with negative MACD). These are partially offset by a more constructive earnings outlook, with management guiding to improving revenue and EBITDA into FY2027 and highlighting margin progress.
Positive Factors
Strong Revenue Growth
Rapid organic revenue expansion demonstrates growing demand for the company’s diagnostic development and manufacturing services. Continued growth at this scale can improve operating leverage, support investment in capabilities, and strengthen Abingdon’s position with customers seeking broader diagnostic support.
Negative Factors
Persistent Losses and Cash Burn
The company remains unable to fund operations internally, despite substantial revenue growth and improved second-half EBITDA. Continued losses and negative operating cash flow can constrain investment, increase reliance on external financing, and delay the point at which growth translates into durable shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid organic revenue expansion demonstrates growing demand for the company’s diagnostic development and manufacturing services. Continued growth at this scale can improve operating leverage, support investment in capabilities, and strengthen Abingdon’s position with customers seeking broader diagnostic support.
Read all positive factors
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£22.75M
Dividend YieldN/A
Average Volume (3M)117.24K
Price to Earnings (P/E)―
Beta (1Y)-0.30
Revenue Growth30.42%
EPS Growth43.16%
CountryUK
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume56,054
30 Day Avg. Volume117,244
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)6.96
Price to Sales (P/S)3.86
P/FCF Ratio-23.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£14.30M
Abingdon Health PLC Business Overview & Revenue Model
Company Description
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-ac...
Abingdon Health PLC Earnings Call Summary
Earnings Call Date:Oct 13, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 31, 2027
Earnings Call Sentiment Positive
The call was predominantly positive. Management highlighted 30% revenue growth, a 47.1% gross margin, a first-half-year adjusted EBITDA profit in H2, 41% compound revenue growth from FY2023 to FY2026, expanding U.K. and U.S. capabilities, and strong contract visibility. The main negatives were the full-year adjusted EBITDA loss, operating cash outflow, flat contract manufacturing revenue, Q1 program delays, contract uncertainty, and a short-term revenue impact from restructuring. Management nevertheless expects revenue and EBITDA performance to improve in FY2027.Positive Updates
Revenue Growth and Higher Grant Income
FY2026 reported revenue increased 30% to approximately GBP 11 million, or GBP 11.3 million including grant-funded project income, compared with GBP 8.4 million in FY2025. Grant income increased to GBP 0.3 million from GBP 0.2 million, relating to the malaria-test project with Institut Pasteur and others.
Negative Updates
Full-Year Adjusted EBITDA Loss
Despite achieving a GBP 0.2 million adjusted EBITDA profit in H2, the company reported an adjusted EBITDA loss of GBP 1.5 million for FY2026 overall.
Read all updates
Q4-2026 Updates
Positive
Negative
Revenue Growth and Higher Grant Income
FY2026 reported revenue increased 30% to approximately GBP 11 million, or GBP 11.3 million including grant-funded project income, compared with GBP 8.4 million in FY2025. Grant income increased to GBP 0.3 million from GBP 0.2 million, relating to the malaria-test project with Institut Pasteur and others.
Read all positive updates
Company Guidance
For financial year '27, management said revenue and adjusted EBITDA will be moved towards the second half, with revenue weighted more towards H2 due to a couple of delays in H1; the Board expects an improved EBITDA position for '27 versus '26, expects revenue to continue to increase, and expects EBITDA performance to improve over last year into this. The U.S. business is expected to generate revenue in the “sort of millions rather than hundreds of thousands” and management would like to see that “step up significantly in the future.” The integration of regulatory services may cause a short-term revenue impact, with a smaller impact on EBITDA, which management expects “to pick back up pretty quickly”; management also said it is “comfortable saying we think we're on for significant growth this year.”Abingdon Health PLC Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
62
Positive
Cash Flow
29
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.99M | 8.43M | 6.13M | 4.04M | 2.83M |
| Gross Profit | 5.18M | 3.13M | 3.68M | 1.40M | -5.23M |
| EBITDA | -2.13M | -3.12M | -916.00K | -2.81M | -19.98M |
| Net Income | -2.13M | -3.42M | -1.27M | -3.47M | -21.26M |
Balance Sheet | |||||
| Total Assets | 10.81M | 9.31M | 5.09M | 6.06M | 12.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 1.92M | 1.44M | 3.24M | 2.40M |
| Total Debt | 1.34M | 1.03M | 1.05M | 1.02M | 1.28M |
| Total Liabilities | 4.71M | 4.01M | 2.84M | 3.05M | 6.34M |
| Stockholders Equity | 6.10M | 5.30M | 2.25M | 3.01M | 6.43M |
Cash Flow | |||||
| Free Cash Flow | -1.79M | -3.43M | -1.70M | 845.00K | -8.49M |
| Operating Cash Flow | -1.60M | -3.10M | -1.66M | 1.00M | -7.74M |
| Investing Cash Flow | -357.00K | -1.43M | -23.00K | -156.00K | -760.00K |
| Financing Cash Flow | 2.95M | 5.08M | -114.00K | -7.00K | 5.92M |
Abingdon Health PLC Technical Analysis
Negative
11.00
Price Trends
10.29
Negative
10.36
Negative
9.49
Negative
Market Momentum
-0.43
Positive
14.25
Positive
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ABDX, the sentiment is Negative. The current price of 11 is above the 20-day moving average (MA) of 9.56, above the 50-day MA of 10.29, and above the 200-day MA of 9.49, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 14.25 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ABDX.
Abingdon Health PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £273.94M | 40.48 | 10.01% | 2.29% | 3.26% | 32.54% | |
64 Neutral | £102.71M | 41.38 | 3.58% | 4.36% | 2.26% | -57.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% | |
46 Neutral | £22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% | |
46 Neutral | £3.69M | -0.63 | -69.62% | ― | -16.27% | -471.21% | |
40 Underperform | £36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
GB:ABDX
Abingdon Health PLC
9.00
2.75
44.00%
GB:NIOX
Circassia Pharmaceuticals
67.60
1.31
1.98%
GB:EKF
EKF Diagnostics Holdings
24.00
-2.20
-8.40%
GB:GDR
Genedrive
0.98
0.01
1.25%
GB:CNSL
Omega Diagnostics
1.55
-1.10
-41.51%
GB:RENX
Renalytix
5.45
-1.93
-26.15%
Abingdon Health PLC Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and Financing
Abingdon Health Delivers Double-Digit Growth and Achieves H2 EBITDA Profitability
Positive
Oct 13, 2026
Abingdon Health reported a strong FY26, with total revenues rising 32% to £11.3m and a transition to adjusted EBITDA profitability in the second half, driven by a 56% surge in contract development revenue and improving gross margins. The grou...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and Financing
Abingdon Health posts 32% revenue rise and reaches H2 EBITDA profitability
Positive
Oct 13, 2026
Abingdon Health reported a strong FY26, with total revenues rising 32% to £11.3m and reported revenue up 30% to £11.0m, driven by a 56% jump in contract development income and improved gross margin to 47.1%. The group achieved adjusted E...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Abingdon Health to unveil 2026 results with live investor briefing
Positive
Oct 7, 2026
Abingdon Health plc, a UK-headquartered med-tech services group specializing in rapid diagnostic tests and regulatory support, will release its final results for the year ended 30 June 2026 on 13 October 2026. The company operates CDMO, regulatory...
Business Operations and StrategyRegulatory Filings and Compliance
Abingdon Health Wins UKAS ISO/IEC 17025 Accreditation for Diagnostic Testing Lab
Positive
Sep 29, 2026
Abingdon Health plc has secured ISO/IEC 17025:2017 accreditation from UKAS for Abingdon Analytical Ltd, its performance evaluation laboratory in Doncaster, England. The certification confirms the lab’s capability to deliver consistently vali...
Business Operations and Strategy
Abingdon Health Opens U.S. Manufacturing Hub to Expand Rapid Diagnostics Footprint
Positive
Sep 25, 2026
Abingdon Health plc has officially opened a new manufacturing hub at its facility in Madison, Wisconsin, marking a significant expansion of its U.S. operations. The site at University Research Park increases infrastructure and capacity to deliver ...
Business Operations and StrategyShareholder Meetings
Abingdon Health to Host Shareholder Open Day at York Headquarters
Positive
Sep 8, 2026
Abingdon Health PLC, a York-headquartered med-tech CDMO and regulatory services provider for rapid diagnostic tests, is expanding engagement with its international shareholder base through an in-person event. The business develops and manufactures...
Business Operations and StrategyFinancial Disclosures
Abingdon Health posts 31% revenue rise and H2 EBITDA profitability
Positive
Jul 29, 2026
Abingdon Health PLC, a specialist in rapid diagnostic test development and manufacturing, has built an integrated CDMO and regulatory services platform that supports international customers from concept through to commercial-scale production. With...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.